MPs in Biological Technology
Navigation Links
MPs in Biological Technology
Announces significant contract with Major Biopharmaceutical Company
BELGIUM, Wis., March 6 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), is pleased to announce that its subsidiary, Modular Process Constructors LLC, is changing its name to MPS BioPharm to better reflect i...
...e (galsulfase) Enzyme Replacement Therapy (ERT) in mps VI (Maroteaux-Lamy Syndrome) patients Presented b...sserstein) -- 1495 -- Clinical Characteristics of mps I patients in the mps I Registry (Bodamer) -- 2241 -- Urinary GAG ...
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2...Kuvan Receives Priority Review Status From Health Canada
...ment for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Jefferies Healthcare Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Goldman Sachs Healthcare Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Deutsche Bank Health Care Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Baird Growth Stock Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin Announces First Quarter 2009 Financial Results
...g programs including PEG-PAL for PKU and GALNS for mps IVA. We are strategically developing earlier stag...ial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase I...Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
...ilize MPS' Equity by Design (TM) product. mps will evaluate all equipment designs for fit and pu...lated to design, constructability and cleanliness. mps will also provide a final report, identifying budg...id, "Equity by Design(TM) is a program whereby mps provides certain Technical Advisory Services in wh...BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
...the advancement of several programs including PEG-PAL for PKU and GALNS for mps IVA. We also plan to continue making investments in growth opportunities a...se 2 PAH trial -- 1Q09/2Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 2Q09: Results from proteinuria in chronic kidney disease trial ...Naglazyme Approved by Brazil's National Health Surveillance Agency
...zil which has the largest known number of affected mps VI patients in the world," said Stephen Aselage, S...) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...t exclusivity in the European Union. About mps VI ...Mach One Corporation Enters Letter of Intent
...saction with Modular Process Constructors LLC (dba mps BioPharm) (the "Seller" or "BioPharm") to acquire ... About Modular Process Constructors LLC (dba mps BioPharm) mps BioPharm currently designs and builds skid based s...Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
... (galsulfase) and enzyme replacement therapies for mps IVA (Morquio Syndrome) and Pompe disease will be p...for symptomatic spinal cord compression (SCC) in a mps VI child: safety, efficacy, and pitfalls" 763/W ...ears of Galsulfase ERT in five adult patients with mps VI" 2353/W - "MPS Brazil-Network: 4 years improv...BioMarin Announces Third Quarter 2008 Financial Results
...xpansion of Naglazyme, and the timely development of the PEG-PAL, GALNS for mps IVA and other promising pipeline programs." Net Product Revenue Net pro...ic kidney disease trial -- 1Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 1Q09/2Q09: Results from PEG-PAL Phase 1 trial -- 1Q09/2Q09: Initia...Naglazyme Approved by Japanese Ministry of Health
...Ges in bringing the first drug treatment option to mps VI patients in Japan," said Stephen Aselage, Senio...C) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...ation in June 2007 from the MHLW in Japan. About mps VI ...BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
...rojects which could lead to important advances for mps I patients." About mps I mps I is a rare, progressive, heterogeneous, debilitat......e (galsulfase) Enzyme Replacement Therapy (ERT) in mps VI (Maroteaux-Lamy Syndrome) patients Presented b...sserstein) -- 1495 -- Clinical Characteristics of mps I patients in the mps I Registry (Bodamer) -- 2241 -- Urinary GAG ...
Genzyme Receives Approval to Market Elaprase(R) in Japan
... Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; Aldurazyme(R) (laronidase) for mps I; and Myozyme(R) (alglucosidase alfa) for Pompe disease. "Our deep experience in Japan in the area of lysosomal storage disorders will enable us to ...Genzyme Begins Major Expansion of Boston Manufacturing Facility
... alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for mps I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the s...Educate, innovate and execute: Wisconsins model for success
...m rather than how much is spent administratively. mps simply spends too much money on employee costs (i....nefits, pension) than is manageable. In fact, the mps Board boosted the tax levy for 2003-'04 by more th...$11 million, or a 5.8 percent increase. This year, mps is projecting a 15% increase as a stopgap to keep ...Other TagsFidelAbusedOutcomesOutcomesComboComboJuiceJuiceConnectionsSeparateOther Contentsneurotransmitterneurotransmitterneurotransmitterneurotransmitterneurotransmitterneurotransmitterneurotransmittermolecularmolecularmolecularmolecularmolecularmolecularmolecularmolecularmolecularmoleculartheorytheorytheorytheorytheorytheorytheoryneutralneutralneutralneutralneutralneutralneutralnondisjunctionendendendendendendendendendendterminalterminalterminalterminalterminalterminalterminalterminalterminallaminalaminalamina
MightyChiropracticFidelAbusedOutcomesAmnesiaComboJuiceRewiringPumpsConnectionsOutwardlyWatchdogSeparate
(Date:11/23/2009)...y of New Hampshire microbiologist Louis Tisa has r...derstanding of the actinorhizal plants, widespread...or and contaminated soils. , The United States ...rofessor of molecular, cellular and biomedical sci...hip between the bacteria Frankia and Casuarina, an...
(Date:11/23/2009)...California biomedical engineer and cardiologist Tz...lp clinicians distinguish cardiac emergencies requ...geable with drugs and lifestyle change. , Angiog...rteries feeding the heart, offer an inside view of...sels, often revealing deposits of a dangerous fatt...
(Date:11/23/2009)... toads have existed for 360 million years and surv...fungus is threatening to make many of them extinct... Microbiology Today . , The fungus, Batrachoc...iated with waves of amphibian extinctions in Centr...,s. Bd infects over 350 amphibian species by penet...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 1Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 2Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1The Caryl Ehrlich Program Discusses Food Addiction on HealthyPlace com 53495 1The Caryl Ehrlich Program Discusses Food Addiction on HealthyPlace com 53495 2(Date:11/25/2009)...lar cancer who were treated with cisplatin-based c...g neurological side effects and Raynaud-like pheno...apy, according to a new study published online Nov...stitute . , Marianne Brydy, M.D., of the Departm... Bergen, Norway, and colleagues conducted a cross-...
(Date:11/25/2009)...grew out of a collaboration between UCLA engineers...e nearly 10 million Americans who suffer from peri...dening of the arteries, peripheral arterial diseas...h narrowed arteries reduce blood flow to the limbs...lar disease, heart attack and stroke, and its prog...
(Date:11/25/2009)...oo short to draw definite conclusions, experts say...s) -- In diabetic patients with blocked coronary a...omes at one year whether patients undergo bypass s...rchers report. , Bypass surgery has been the st...ry artery disease. However, less invasive approach...
(Date:11/25/2009)...tion and treatment clinics to resume Monday, Nov. ...vember 25, 2009 -- Centegra Health System is conti...e shots at four Centegra Primary Care (CPC) vaccin...s arrived. The clinics are at CPC sites in Huntley...open as follows: , From 4:30 to 7:30...
(Date:11/25/2009)...logical symptoms, study finds , , WEDNE...e effects are among the potential problems faced b...e treated with cisplatin-based chemotherapy, a new...rwegian men treated for unilateral testicular canc...-up survey conducted from 1998 to 2002. , The r...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4[0] News brief: Long-term testicular cancer survivors at high risk for neurological side effects[1] Engineers, doctors at UCLA develop novel material that could help fight arterial disease[1] Stenting May Equal Bypass for Diabetic Heart Patients [0] Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1[0] Long-Term Problems Linked to Testicular Cancer Chemo
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |